FT.com

For World TB Day, the Financial Times’ Andrew Jack interviewed various members of the TB community to get their take on a range of topics:

Today marks the launch of an exciting new initiative in TB R&D. The US Food and Drug Administration (FDA) has supported the Critical Path to TB Drug Regimens (CPTR). The CPTR comprises a broad collaborative network of partners including pharmaceutical companies, government, academia, and advocates, and NGOs with the focus to accelerate the development of new, safe, and highly effective shorter length TB treatment regimens.

Why is this initiative so important?